Metropolitan Life Insurance CO Altimmune, Inc. Transaction History

Metropolitan Life Insurance CO

  • $252 Million
  • Q4 2024

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023
BUY
$3.45 - $5.97 $9,408 - $16,280
2,727 New
2,727 $9,000
Q2 2022

Aug 11, 2022
SELL
$3.94 - $11.77 $11,055 - $33,026
-2,806 Closed
0 $0
Q1 2022

Jun 20, 2023
BUY
$5.9 - $9.45 $16,555 - $26,516
2,806 New
2,806 $17,000
Q1 2022

Mar 30, 2023
SELL
$5.9 - $9.45 $48,645 - $77,915
-8,245 Reduced 74.61%
2,806 $17,000
Q1 2022

May 12, 2022
SELL
$5.9 - $9.45 $48,645 - $77,915
-8,245 Reduced 74.61%
2,806 $17,000
Q4 2021

Jun 21, 2023
BUY
$8.69 - $12.48 $96,033 - $137,916
11,051 New
11,051 $101,000
Q4 2021

Mar 30, 2023
BUY
$8.69 - $12.48 $7,803 - $11,207
898 Added 8.84%
11,051 $101,000
Q4 2021

Feb 15, 2022
BUY
$8.69 - $12.48 $7,803 - $11,207
898 Added 8.84%
11,051 $101,000
Q3 2021

Jun 21, 2023
BUY
$8.43 - $16.81 $85,589 - $170,671
10,153 New
10,153 $114,000
Q3 2021

Mar 30, 2023
BUY
$8.43 - $16.81 $2,984 - $5,950
354 Added 3.61%
10,153 $114,000
Q3 2021

Nov 15, 2021
BUY
$8.43 - $16.81 $2,984 - $5,950
354 Added 3.61%
10,153 $115,000
Q2 2021

Jun 21, 2023
BUY
$9.85 - $16.46 $96,520 - $161,291
9,799 New
9,799 $96,000
Q2 2021

Mar 30, 2023
BUY
$9.85 - $16.46 $96,520 - $161,291
9,799 New
9,799 $96,000
Q2 2021

Aug 16, 2021
BUY
$9.85 - $16.46 $96,520 - $161,291
9,799 New
9,799 $97,000

Others Institutions Holding ALT

# of Institutions
208
Shares Held
39.5M
Call Options Held
1.94M
Put Options Held
1.38M
View Full List

About Altimmune, Inc.

ALT Quotes by TradingView
  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $315M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email